Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
고수익 성장
회사의 순이익은 업계 선두를 달리고 있으며, 최근 연간 순이익은 미화 2.09B에 달합니다.
과소 평가된
회사의 최신 PE은 21.46로, 최근 3년 기준 낮은 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 161.40M주이며, 전 분기 대비 15.71% 감소했습니다.